InMed Pharmaceuticals to Report Second Quarter Fiscal 2021 Financial Results

Rhea-AI Summary

InMed Pharmaceuticals Inc. (NASDAQ: INM), a clinical-stage pharmaceutical company, is set to report its financial results for Q2 of fiscal year 2021 on February 11, 2021. The company focuses on developing cannabinoid-based medications, specifically cannabinol (CBN) for diseases with high unmet medical needs. A conference call and webcast will take place on the same day at 8:30 AM PT with details available on their website. InMed emphasizes its commitment to delivering therapeutic alternatives while navigating the uncertainties inherent in clinical development.

Positive

• Focused on cannabinoid-based medications targeting high unmet medical needs.
• Scheduled financial results report that may provide insights into business performance.

Negative

• Uncertainty surrounding forward-looking statements may affect investor confidence.

VANCOUVER, BC, Feb. 5, 2021 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"),  will report financial results for the second quarter of fiscal year 2021 ending December 31, 2020, on Thursday, February 11, 2021.

Conference Call & Webcast¹:

Thursday, February 11, 2021 at 8:30 AM Pacific Time, 11:30 AM Eastern Time
Local - Toronto	(+1) 416-764-8609
Local - Vancouver	(+1) 778-383-7417
Toll Free - North America	(+1) 888-390-0605
Conference ID:	19917866
Webcast: https://produceredition.webcasts.com/starthere.jsp?ei=1425283&tp_key=9f171376cb
(1Webcast replay available for 90 days)

Dial-In Replays²:

Toronto:	(+1) 416-764-8677
North America (Toll Free):	(+1) 888-390-0541
Playback Passcode:	917866 #
(2Dial-in replay available until February 18, 2021)

The Company's full financial statements and related MD&A for the second quarter December 31, 2020 will be available at www.inmedpharma.com, www.sedar.com and at www.sec.gov on February 11, 2021.

About InMed: InMed Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of cannabinoid-based medications, initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need. The Company is dedicated to delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based medicines. For more information, visit www.inmedpharma.com.

Cautionary Note Regarding Forward-Looking Information:

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws.  Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.  Forward-looking information in this news release includes statements about: delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based medicines; developing a pipeline of cannabinoid-based medications, initially focused on the therapeutic benefits of cannabinol; leading the way in the clinical development of cannabinol; and reporting financial results on February 11, 2021.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

NEITHER THE TORONTO STOCK EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

View original content:http://www.prnewswire.com/news-releases/inmed-pharmaceuticals-to-report-second-quarter-fiscal-2021-financial-results-301223390.html

SOURCE InMed Pharmaceuticals Inc.

FAQ

When will InMed Pharmaceuticals report its Q2 fiscal 2021 financial results?

InMed Pharmaceuticals will report its Q2 fiscal 2021 financial results on February 11, 2021.

What is the focus of InMed Pharmaceuticals' development?

InMed Pharmaceuticals is focused on developing cannabinoid-based medications, particularly cannabinol (CBN), for diseases with high unmet medical needs.

What time is the InMed Pharmaceuticals conference call on February 11, 2021?

The conference call is scheduled for 8:30 AM Pacific Time on February 11, 2021.

What risks are associated with InMed Pharmaceuticals' forward-looking statements?

The forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those projected.

Where can investors find InMed Pharmaceuticals' financial statements?

Investors can find InMed Pharmaceuticals' financial statements on their website, as well as on SEDAR and the SEC's website.